Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer projected total revenues between $61.0 billion and $64.0 billion. The Zacks Consensus Estimate for the metric is pegged at $62.86 billion. Adjusted earnings are expected in the range of $2.80 to $3.00. The Zacks Consensus Estimate is pegged at $2.90 per share. The company's sales and earnings projections for 2025 were within investor expectations. Many analysts believe the guidance is achievable. Pfizer also maintained its previously issued financial guidance for 2024. Pfizer expects total revenues in 2024 to be in the range of $61.0 to $64.0 billion while adjusted earnings are expected in the range of $2.75 to $2.95 per share. Excluding revenues from its COVID products, Comirnaty and Paxlovid, Pfizer expects total revenues to increase 9% to 11% on an operational basis in 2024. Pfizer's stock has declined 8.2% in the year-to-date period against an increase of 5.3% for the industry. Zacks Investment Research Image Source: Zacks Investment Research PFE's 2025 Guidanc
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire
- Is Pfizer (PFE) a Cheap NYSE Stock to Invest in Now? [Yahoo! Finance]Yahoo! Finance
- Why Pfizer (PFE) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- GoComet's Odyssey Singapore 2024 Highlights: When Supply Chain Giants MeetPR Web
PFE
Earnings
- 10/29/24 - Beat
PFE
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 8-K
- PFE's page on the SEC website